MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Eli Lilly and Co.

Отворен

СекторЗдравеопазване

802.67 -2.75

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

796.87

Максимум

824

Ключови измерители

By Trading Economics

Приходи

3.4B

4.4B

Продажби

2.1B

14B

P/E

Средно за сектора

73.734

73.239

EPS

5.32

Дивидентна доходност

0.72

Марж на печалбата

32.586

Служители

47,000

EBITDA

1.2B

6.1B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+23.83% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.72%

3.06%

Следващи печалби

1.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-8B

777B

Предишно отваряне

805.42

Предишно затваряне

802.67

Настроения в новините

By Acuity

46%

54%

152 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

Eli Lilly and Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.03.2025 г., 15:54 ч. UTC

Топ новини

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

14.03.2025 г., 09:30 ч. UTC

Топ новини

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26.02.2025 г., 15:14 ч. UTC

Топ новини

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

26.02.2025 г., 14:30 ч. UTC

Топ новини

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

10.02.2025 г., 12:00 ч. UTC

Топ новини

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7.02.2025 г., 10:30 ч. UTC

Топ новини

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6.02.2025 г., 16:16 ч. UTC

Топ новини
Печалби

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6.02.2025 г., 14:56 ч. UTC

Печалби

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

6.02.2025 г., 14:32 ч. UTC

Пазарно говорене
Печалби

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

6.02.2025 г., 13:18 ч. UTC

Топ новини
Печалби

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

6.02.2025 г., 12:24 ч. UTC

Печалби

Eli Lilly Stock Rises After Earnings Beat, Upbeat Guidance -- Barrons.com

6.02.2025 г., 12:01 ч. UTC

Печалби

Eli Lilly Stock Rises After Earnings Beat -- Barrons.com

6.02.2025 г., 11:49 ч. UTC

Печалби

Eli Lilly Sees Producing at Least 1.6 Times Amount of Salable Incretin Doses in 1st Half of 2025 Vs 1st Half of 2024 >LLY

6.02.2025 г., 11:48 ч. UTC

Печалби

Eli Lilly 4Q U.S. Zepbound Revenue $1.91B >LLY

6.02.2025 г., 11:47 ч. UTC

Печалби

Eli Lilly 4Q Worldwide Mounjaro Revenue Rose 60% to $3.53B >LLY

6.02.2025 г., 11:46 ч. UTC

Печалби

Eli Lilly 4Q Gross Margin 82.2% >LLY

6.02.2025 г., 11:45 ч. UTC

Печалби

Eli Lilly 4Q Trulicity Rev $1.25B >LLY

6.02.2025 г., 11:45 ч. UTC

Печалби

Eli Lilly Sees FY Adj EPS $22.50-Adj EPS $24.00 >LLY

6.02.2025 г., 11:45 ч. UTC

Печалби

Eli Lilly 4Q Humalog Rev $619.9M >LLY

6.02.2025 г., 11:45 ч. UTC

Печалби

Eli Lilly Sees FY Rev $58B-$61B >LLY

6.02.2025 г., 11:45 ч. UTC

Печалби

Eli Lilly 4Q Net $4.41B >LLY

6.02.2025 г., 11:45 ч. UTC

Печалби

Eli Lilly 4Q EPS $4.88 >LLY

6.02.2025 г., 11:45 ч. UTC

Печалби

Eli Lilly Sees FY EPS $22.05-EPS $23.55 >LLY

6.02.2025 г., 11:45 ч. UTC

Печалби

Eli Lilly 4Q Jardiance Rev $1.2B >LLY

6.02.2025 г., 11:45 ч. UTC

Печалби

Eli Lilly 4Q Rev $13.53B >LLY

6.02.2025 г., 11:45 ч. UTC

Печалби

Eli Lilly 4Q Adj EPS $5.32 >LLY

5.02.2025 г., 21:23 ч. UTC

Топ новини

Eli Lilly's Results Already Disappointed the Street. More Details Come Thursday. -- Barrons.com

5.02.2025 г., 12:02 ч. UTC

Печалби

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

5.02.2025 г., 12:00 ч. UTC

Топ новини

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Eli Lilly and Co. Прогноза

Ценова цел

By TipRanks

23.83% нагоре

12-месечна прогноза

Среден 1,022.71 USD  23.83%

Висок 1,146 USD

Нисък 900 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Eli Lilly and Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

19 ratings

18

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

824.76 / 836.29Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

152 / 386 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.